Intravenous crotoxin for advanced solid tumors
Part of Cancer clinical trials.
This trial tests an experimental drug called crotoxin, given through an IV, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it can slow or stop tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a solid tumor that has spread or is advanced, and standard treatments have stopped working or are not available.
- You must be able to take care of yourself (up and about, though not necessarily able to do heavy work).
- You must have finished chemotherapy, radiation, or other cancer treatments at least 4 weeks before starting the trial.
- Your blood counts and liver and kidney function must be within acceptable ranges.
- You must not have had a severe allergic reaction to venoms in the past.
- You must not have brain metastases or certain other conditions that would make the trial unsafe.
- You must live within about 30 km (18 miles) of the hospital and have a mobile phone for emergencies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if injecting chemotherapy directly into tumors can help people with advanced solid cancers that have stopped responding to standard treatments. It aims to see how safe and effective this approach is.
This trial tests an experimental drug called CR-001 in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if CR-001 can slow or stop tumor growth.
This trial tests a personalized treatment that uses your own immune cells, modified to recognize and attack your cancer. It may help people with advanced solid tumors who have not improved with standard treatments.
This trial tests an experimental cell therapy for people with advanced solid tumors that have not responded to standard treatments. It targets tumors with specific genetic markers (KRAS or NRAS G12D and HLA-A*11:01) to see if it can shrink or slow the cancer.
This trial tests an experimental drug (TGRX-1942) for people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goal is to find a safe dose and see how well the drug works.
This trial tests an experimental drug called MHB046C for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow their growth.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.